

MEDIA CONTACTS

Julie McDowell
CAP
800-832-7844
jmcdowe@cap.org

Chris Martin
IASLC
630-670-2745
cmartin@davidjamesgroup.com

Andrew Noble
AMP
415-722-2129
anoble@amp.org

International Lung Cancer Experts Seek Public Comments on Updated Molecular Testing Guideline to Improve Patient Selection and Targeted Therapies

ROCKVILLE, MD — August 22, 2024 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.”

“Rapid advancements in adjuvant and neoadjuvant therapy for patients with early-stage non-small cell lung carcinoma make this revision essential to guide optimal patient care,” said guideline update co-chair Sinchita Roy-Chowdhuri, MD, PhD, FCAP, Professor of Pathology at The University of Texas MD Anderson Cancer Center. “This revised guideline provides a clear framework based on evidence from recently published clinical literature.”

For more information and to provide comments, visit

<https://www.amp.org/opencomment/>

“The final manuscript will serve as both an update and extension of the 2013 and 2018 practice guidelines that established evidence-based best practices for molecular biomarker testing for patients diagnosed with lung adenocarcinoma,” said Neal I. Lindeman, MD, guideline update co-chair, the Faculty Distinguished Professor of Pathology and Laboratory Medicine II at Weill Cornell Medicine. “We will continue to update this guideline as appropriate, and we will add guidelines for other biomarkers associated with lung cancer as medical knowledge and clinical practice continue to advance.”

Together with a multi-disciplinary expert panel, co-chair Drs. Roy-Chowdhuri, Dacic, and Lindeman formulated new draft recommendations addressing the following key questions:

- In patients with NSCLC being considered for molecularly targeted therapies, does biomarker testing improve treatment response rates and overall survival?

- In patients with NSCLC being considered for molecularly targeted therapies, does biomarker testing improve overall survival?

